Clinical Trials Directory

Trials / Sponsors / Tarix Pharmaceuticals

Tarix Pharmaceuticals

Industry · 8 registered clinical trials.

StatusTrialPhaseStarted
WithdrawnEfficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood
Hematologic Malignancies
Phase 22013-12-01
WithdrawnEfficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord
Hematologic Malignancies
Phase 22013-12-01
WithdrawnEvaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients
Cord Blood Transplant, Hematologic Malignancy, Inherited Metabolic Disease
Phase 22012-03-01
TerminatedPhase I Study Evaluating TXA127 in Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia
Myelodysplastic Syndrome (MDS)
Phase 12011-04-01
TerminatedTXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation
Double Cord Blood Transplant, Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Phase 12011-01-01
TerminatedAcceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin
Lymphoma, Non-Hodgkin, Hodgkin Disease, Multiple Myeloma
Phase 22010-06-01
CompletedSafety and Efficacy of TXA127 and Neupogen to Increase Peripheral Blood Stem Cells (PBSCs)
Miscellaneous Peripheral Blood Cell Abnormalities
Phase 12009-12-01
CompletedStudy of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal
Thrombocytopenia, Neutropenia, Lymphopenia
Phase 22008-10-01